CG
CRL icon

CFO4Life Group’s Charles River Laboratories CRL Stock Holding History

CFO4Life Group’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-2,275
Closed -$939K – 159
2021
Q3 		$939K Sell
2,275
-63
-3% -$26.2K 0.22% 51
2021
Q2 		$865K Buy
2,338
+7
+0.3% +$2.34K 0.2% 56
2021
Q1 		$676K Sell
2,331
-67
-3% -$18.6K 0.17% 65
2020
Q4 		$599K Sell
2,398
-104
-4% -$24.8K 0.17% 67
2020
Q3 		$567K Buy
2,502
+500
+25% +$104K 0.19% 56
2020
Q2 		$349K Sell
2,002
-648
-24% -$103K 0.13% 75
2020
Q1 		$334K Buy
+2,650
New +$397K 0.18% 78

Other funds holding CRL

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Kayne Anderson Rudnick Investment Management
Kayne Anderson Rudnick Investment Management Los Angeles, California $34B AUM 6.31% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

CFO4Life Group's CRL Position: Q4 2021 in Review

CFO4Life Group sold out of Charles River Laboratories (CRL) in Q4 2021, closing a stake of 2,275 shares — an estimated $939K sold.

CFO4Life Group first reported a position in CRL in Q1 2020 and held it in 7 quarters. The position peaked at $939K in Q3 2021. 707 funds tracked by Wall St. Rank hold CRL as of Q4 2021.

  • CFO4Life Group reported no remaining Charles River Laboratories position as of Q4 2021 after selling out during the quarter.
  • CFO4Life Group sold 2,275 Charles River Laboratories shares in Q4 2021, an estimated $939K.
  • CFO4Life Group first reported a position in Charles River Laboratories in Q1 2020 and held it in 7 quarters.
  • CFO4Life Group's Charles River Laboratories position peaked at $939K in Q3 2021.
  • 707 funds tracked by Wall St. Rank held Charles River Laboratories as of Q4 2021.

Based on CFO4Life Group's 13F filing for Q4 2021, filed 10 Feb 2022.